Vera Therapeutics, Inc. VERA
We take great care to ensure that the data presented and summarized in this overview for Vera Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VERA
View all-
Avoro Capital Advisors LLC New York, NY4.31MShares$178 Million2.87% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.94MShares$163 Million0.02% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$138 Million0.0% of portfolio
-
Abingworth LLP London, X02.96MShares$122 Million19.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.79MShares$116 Million11.68% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.58MShares$107 Million0.0% of portfolio
-
Commodore Capital LP New York, NY2.48MShares$102 Million9.29% of portfolio
-
Eversept Partners, LP New York, NY2.05MShares$84.8 Million7.17% of portfolio
-
Holocene Advisors, LP New York, NY1.95MShares$80.8 Million0.38% of portfolio
-
State Street Corp Boston, MA1.82MShares$75.4 Million0.0% of portfolio
Latest Institutional Activity in VERA
Top Purchases
Top Sells
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Insider Transactions at VERA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
57,661
+28.65%
|
$115,322
$2.9 P/Share
|
|
Dec 18
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
17,500
-3.89%
|
$752,500
$43.01 P/Share
|
|
Dec 18
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+3.73%
|
$35,000
$2.9 P/Share
|
|
Dec 11
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
17,500
-4.44%
|
$822,500
$47.26 P/Share
|
|
Dec 11
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+3.95%
|
$35,000
$2.9 P/Share
|
|
Nov 25
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
19,375
-4.23%
|
$930,000
$48.36 P/Share
|
|
Nov 25
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,375
+3.99%
|
$38,750
$2.9 P/Share
|
|
Nov 18
2024
|
Jason S Carter Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,000
+50.0%
|
-
|
|
Nov 13
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
30,625
-3.65%
|
$1,500,625
$49.84 P/Share
|
|
Nov 13
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,625
+3.4%
|
$61,250
$2.9 P/Share
|
|
Oct 28
2024
|
Beth C Seidenberg |
SELL
Open market or private sale
|
Direct |
15,000
-5.13%
|
$720,000
$48.78 P/Share
|
|
Oct 23
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
19,375
-1.53%
|
$794,375
$41.03 P/Share
|
|
Oct 23
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,375
+1.48%
|
$38,750
$2.9 P/Share
|
|
Oct 09
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
15,625
-2.45%
|
$593,750
$38.46 P/Share
|
|
Oct 09
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,625
+2.38%
|
$31,250
$2.9 P/Share
|
|
Sep 25
2024
|
Marshall Fordyce PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
23,125
-0.67%
|
$1,063,750
$46.19 P/Share
|
|
Sep 25
2024
|
Marshall Fordyce PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
23,125
+0.66%
|
$46,250
$2.9 P/Share
|
|
Sep 19
2024
|
Beth C Seidenberg |
SELL
Open market or private sale
|
Direct |
13,823
-8.62%
|
$580,566
$42.31 P/Share
|
|
Sep 18
2024
|
Beth C Seidenberg |
SELL
Open market or private sale
|
Indirect |
1,476
-26.9%
|
$61,992
$42.0 P/Share
|
|
Sep 18
2024
|
Beth C Seidenberg |
SELL
Open market or private sale
|
Direct |
1,177
-0.73%
|
$49,434
$42.01 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 180K shares |
|---|---|
| Exercise of conversion of derivative security | 390K shares |
| Open market or private purchase | 161K shares |
| Open market or private sale | 2.29M shares |
|---|